Review



tissue microarray tma slides  (Proteintech)


Bioz Verified Symbol Proteintech is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 93

    Structured Review

    Proteintech tissue microarray tma slides
    Tissue Microarray Tma Slides, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 12 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/tissue microarray tma slides/product/Proteintech
    Average 93 stars, based on 12 article reviews
    tissue microarray tma slides - by Bioz Stars, 2026-03
    93/100 stars

    Images



    Similar Products

    90
    SuperBioChips tissue microarray (tma) slides
    Tissue Microarray (Tma) Slides, supplied by SuperBioChips, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/tissue microarray (tma) slides/product/SuperBioChips
    Average 90 stars, based on 1 article reviews
    tissue microarray (tma) slides - by Bioz Stars, 2026-03
    90/100 stars
      Buy from Supplier

    93
    Proteintech tissue microarray tma slides
    Tissue Microarray Tma Slides, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/tissue microarray tma slides/product/Proteintech
    Average 93 stars, based on 1 article reviews
    tissue microarray tma slides - by Bioz Stars, 2026-03
    93/100 stars
      Buy from Supplier

    90
    TissueArray.com LLC tissue microarray (tma) slides containing 110 tnbc cases
    (A) cBioportal data for breast cancer tumors shows USP7 is recurrently amplified and overexpressed in breast cancer. Red=amplification; pink=increased expression; blue=deletion; light blue=decreased expression. (B) TCGA breast cancer database shows USP7 mRNA expression is elevated across all breast cancer tumors (n=1085, red) compared to normal breast tissue (n=291, grey). (C) Analysis of DepMap data on the effect of USP7 CRISPR KO on breast cancer cell fitness/proliferation separated by pathologic breast cancer subtypes. (D) Overall survival analysis from the METABRIC breast cancer database shows high USP7 expression correlates with poorer survival (n=1904). Patients grouped into quartiles based on USP7 expression: Q1 (yellow)=lowest USP7 expression; Q4 (magenta)=highest USP7 expression. Log-rank test p=0.0031, HR=1.34. (E) Representative IHC images of core human tissues from a <t>TNBC</t> tissue microarray stained for USP7. (F) Heat map showing percentage of core tissues with low, medium, or high USP7 protein levels, subdivided into TNBC stage I, II, or III.
    Tissue Microarray (Tma) Slides Containing 110 Tnbc Cases, supplied by TissueArray.com LLC, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/tissue microarray (tma) slides containing 110 tnbc cases/product/TissueArray.com LLC
    Average 90 stars, based on 1 article reviews
    tissue microarray (tma) slides containing 110 tnbc cases - by Bioz Stars, 2026-03
    90/100 stars
      Buy from Supplier

    90
    SuperBioChips tissue microarray (tma) slides containing snip, sinonasal malignancy, and control tissue samples
    Schematic workflow for the identification and verification of biomarkers <t>for</t> <t>sinonasal</t> inverted papilloma <t>(SNIP).</t>
    Tissue Microarray (Tma) Slides Containing Snip, Sinonasal Malignancy, And Control Tissue Samples, supplied by SuperBioChips, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/tissue microarray (tma) slides containing snip, sinonasal malignancy, and control tissue samples/product/SuperBioChips
    Average 90 stars, based on 1 article reviews
    tissue microarray (tma) slides containing snip, sinonasal malignancy, and control tissue samples - by Bioz Stars, 2026-03
    90/100 stars
      Buy from Supplier

    90
    Biomax Inc melanoma tissue microarray (tma) slides
    Upregulation of MHC class II antigen in human melanoma xenografts treated systemically with anle138b, and expression of α-synuclein, MHC class II, and MHC class I proteins in melanoma <t>TMA</t> cores. (a) A tissue section from a nontreated WM983-B tumor xenograft probed with an antibody to human MHC class II (HLA-DPB1) protein (pseudocolored green). (b) A tissue section from an anle138b-treated WM983-B tumor xenograft probed with an antibody to human MHC class II (HLA-DPB1) protein (pseudocolored green). (c) Fluorescence intensity level of expression of proteins – α-synuclein (pseudocolored red), MHC II (pseudocolored yellow), MHC I (pseudocolored green) – in areas, encircled by a white line, in tissue sections from three of the Stage II and from one of the Stage IV melanoma TMA cores in which α-synuclein or vice versa, MHC II, or MHC I protein was expressed more strongly. TMA, tissue <t>microarray.</t>
    Melanoma Tissue Microarray (Tma) Slides, supplied by Biomax Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/melanoma tissue microarray (tma) slides/product/Biomax Inc
    Average 90 stars, based on 1 article reviews
    melanoma tissue microarray (tma) slides - by Bioz Stars, 2026-03
    90/100 stars
      Buy from Supplier

    90
    TissueArray.com LLC paraffin-embedded human bc tissue microarray (tma) slides
    Upregulation of MHC class II antigen in human melanoma xenografts treated systemically with anle138b, and expression of α-synuclein, MHC class II, and MHC class I proteins in melanoma <t>TMA</t> cores. (a) A tissue section from a nontreated WM983-B tumor xenograft probed with an antibody to human MHC class II (HLA-DPB1) protein (pseudocolored green). (b) A tissue section from an anle138b-treated WM983-B tumor xenograft probed with an antibody to human MHC class II (HLA-DPB1) protein (pseudocolored green). (c) Fluorescence intensity level of expression of proteins – α-synuclein (pseudocolored red), MHC II (pseudocolored yellow), MHC I (pseudocolored green) – in areas, encircled by a white line, in tissue sections from three of the Stage II and from one of the Stage IV melanoma TMA cores in which α-synuclein or vice versa, MHC II, or MHC I protein was expressed more strongly. TMA, tissue <t>microarray.</t>
    Paraffin Embedded Human Bc Tissue Microarray (Tma) Slides, supplied by TissueArray.com LLC, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/paraffin-embedded human bc tissue microarray (tma) slides/product/TissueArray.com LLC
    Average 90 stars, based on 1 article reviews
    paraffin-embedded human bc tissue microarray (tma) slides - by Bioz Stars, 2026-03
    90/100 stars
      Buy from Supplier

    90
    Pantomics Inc tissue microarray tma slides
    Upregulation of MHC class II antigen in human melanoma xenografts treated systemically with anle138b, and expression of α-synuclein, MHC class II, and MHC class I proteins in melanoma <t>TMA</t> cores. (a) A tissue section from a nontreated WM983-B tumor xenograft probed with an antibody to human MHC class II (HLA-DPB1) protein (pseudocolored green). (b) A tissue section from an anle138b-treated WM983-B tumor xenograft probed with an antibody to human MHC class II (HLA-DPB1) protein (pseudocolored green). (c) Fluorescence intensity level of expression of proteins – α-synuclein (pseudocolored red), MHC II (pseudocolored yellow), MHC I (pseudocolored green) – in areas, encircled by a white line, in tissue sections from three of the Stage II and from one of the Stage IV melanoma TMA cores in which α-synuclein or vice versa, MHC II, or MHC I protein was expressed more strongly. TMA, tissue <t>microarray.</t>
    Tissue Microarray Tma Slides, supplied by Pantomics Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/tissue microarray tma slides/product/Pantomics Inc
    Average 90 stars, based on 1 article reviews
    tissue microarray tma slides - by Bioz Stars, 2026-03
    90/100 stars
      Buy from Supplier

    Image Search Results


    (A) cBioportal data for breast cancer tumors shows USP7 is recurrently amplified and overexpressed in breast cancer. Red=amplification; pink=increased expression; blue=deletion; light blue=decreased expression. (B) TCGA breast cancer database shows USP7 mRNA expression is elevated across all breast cancer tumors (n=1085, red) compared to normal breast tissue (n=291, grey). (C) Analysis of DepMap data on the effect of USP7 CRISPR KO on breast cancer cell fitness/proliferation separated by pathologic breast cancer subtypes. (D) Overall survival analysis from the METABRIC breast cancer database shows high USP7 expression correlates with poorer survival (n=1904). Patients grouped into quartiles based on USP7 expression: Q1 (yellow)=lowest USP7 expression; Q4 (magenta)=highest USP7 expression. Log-rank test p=0.0031, HR=1.34. (E) Representative IHC images of core human tissues from a TNBC tissue microarray stained for USP7. (F) Heat map showing percentage of core tissues with low, medium, or high USP7 protein levels, subdivided into TNBC stage I, II, or III.

    Journal: bioRxiv

    Article Title: USP7 inhibition perturbs proteostasis and tumorigenesis in triple negative breast cancer

    doi: 10.1101/2025.01.28.635372

    Figure Lengend Snippet: (A) cBioportal data for breast cancer tumors shows USP7 is recurrently amplified and overexpressed in breast cancer. Red=amplification; pink=increased expression; blue=deletion; light blue=decreased expression. (B) TCGA breast cancer database shows USP7 mRNA expression is elevated across all breast cancer tumors (n=1085, red) compared to normal breast tissue (n=291, grey). (C) Analysis of DepMap data on the effect of USP7 CRISPR KO on breast cancer cell fitness/proliferation separated by pathologic breast cancer subtypes. (D) Overall survival analysis from the METABRIC breast cancer database shows high USP7 expression correlates with poorer survival (n=1904). Patients grouped into quartiles based on USP7 expression: Q1 (yellow)=lowest USP7 expression; Q4 (magenta)=highest USP7 expression. Log-rank test p=0.0031, HR=1.34. (E) Representative IHC images of core human tissues from a TNBC tissue microarray stained for USP7. (F) Heat map showing percentage of core tissues with low, medium, or high USP7 protein levels, subdivided into TNBC stage I, II, or III.

    Article Snippet: Tissue microarray (TMA) slides containing 110 TNBC cases were obtained from US Biomax (BRE1201; TissueArray.com ).

    Techniques: Amplification, Expressing, CRISPR, Microarray, Staining

    (A) Western Blot analysis showing USP7 protein expression levels in malignant breast cancer cells, including TNBC, compared to the non-malignant MCF10A mammary epithelial cell line used as control. Quantification relative to MCF10A expression shown at the bottom after β-actin normalization. β-actin was used as loading control. (B) Representative Western blot analysis of USP7 in CRISPR/Cas9-mediated USP7 knockout (USP7 KO) clones of TNBC cell lines in comparison to non-targeting vector control (Ctrl). β-actin was used as loading control. (C) Bar graph of colony counts from clonogenic assays comparing USP7 KO to Ctrl. (D) Chemical structures of USP7 inhibitors that were used for in vitro assays. (E) Representative images of colonies stained with crystal violet comparing SUM159 treated with XL177A or FT671. DMSO used as vehicle control. (F) Bar graph of colony counts from clonogenic assays comparing TNBC cells treated with XL177A or FT671. DMSO as control. (G) Representative image from scratch-wound assay comparing wound closure of SUM159 non-targeting vector control (Ctrl) and USP7 KO clone over 8 hours. White lines represent the wound edge. (H) Quantification of the distance cells migrated in scratch-wound assays for each TNBC cell line. (I) Representative images from Transwell invasion assays with cells stained with crystal violet comparing SUM159 Ctrl and USP7 KO clone. (J) Quantification of the number of cells invaded across a Transwell membrane for each of the TNBC cell lines. (K) Quantification of the distance cells migrated for TNBC cells treated with XL177A or FT671. DMSO used as vehicle control. (L) Quantification of cell invasion for TNBC cells treated with XL177A or FT671. DMSO used as vehicle control. (M) Quantification of the distance cells migrated normalized to DMSO for MDA-MB-231 Ctrl and USP7 KO. (N) Quantification of cell invasion normalized to DMSO for MDA-MB-231 Ctrl and USP7 KO. For all bar graphs, values were normalized to control. Each bar is shown as mean ± SD, with each dot representing an independent replicate, n= 3. For all graphs: ns=not significant, *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001 by unpaired two-tailed t test.

    Journal: bioRxiv

    Article Title: USP7 inhibition perturbs proteostasis and tumorigenesis in triple negative breast cancer

    doi: 10.1101/2025.01.28.635372

    Figure Lengend Snippet: (A) Western Blot analysis showing USP7 protein expression levels in malignant breast cancer cells, including TNBC, compared to the non-malignant MCF10A mammary epithelial cell line used as control. Quantification relative to MCF10A expression shown at the bottom after β-actin normalization. β-actin was used as loading control. (B) Representative Western blot analysis of USP7 in CRISPR/Cas9-mediated USP7 knockout (USP7 KO) clones of TNBC cell lines in comparison to non-targeting vector control (Ctrl). β-actin was used as loading control. (C) Bar graph of colony counts from clonogenic assays comparing USP7 KO to Ctrl. (D) Chemical structures of USP7 inhibitors that were used for in vitro assays. (E) Representative images of colonies stained with crystal violet comparing SUM159 treated with XL177A or FT671. DMSO used as vehicle control. (F) Bar graph of colony counts from clonogenic assays comparing TNBC cells treated with XL177A or FT671. DMSO as control. (G) Representative image from scratch-wound assay comparing wound closure of SUM159 non-targeting vector control (Ctrl) and USP7 KO clone over 8 hours. White lines represent the wound edge. (H) Quantification of the distance cells migrated in scratch-wound assays for each TNBC cell line. (I) Representative images from Transwell invasion assays with cells stained with crystal violet comparing SUM159 Ctrl and USP7 KO clone. (J) Quantification of the number of cells invaded across a Transwell membrane for each of the TNBC cell lines. (K) Quantification of the distance cells migrated for TNBC cells treated with XL177A or FT671. DMSO used as vehicle control. (L) Quantification of cell invasion for TNBC cells treated with XL177A or FT671. DMSO used as vehicle control. (M) Quantification of the distance cells migrated normalized to DMSO for MDA-MB-231 Ctrl and USP7 KO. (N) Quantification of cell invasion normalized to DMSO for MDA-MB-231 Ctrl and USP7 KO. For all bar graphs, values were normalized to control. Each bar is shown as mean ± SD, with each dot representing an independent replicate, n= 3. For all graphs: ns=not significant, *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001 by unpaired two-tailed t test.

    Article Snippet: Tissue microarray (TMA) slides containing 110 TNBC cases were obtained from US Biomax (BRE1201; TissueArray.com ).

    Techniques: Western Blot, Expressing, Control, CRISPR, Knock-Out, Clone Assay, Comparison, Plasmid Preparation, In Vitro, Staining, Scratch Wound Assay Assay, Membrane, Two Tailed Test

    (A) Schematic describing the quantitative proteomics workflow for the USP7 inhibitor (USP7i) analysis. SUM149, SUM159, and MDA-MB-231 TNBC cell lines were grown and treated with DMSO, 1 μM FT671, or 1 μM XL177A for 8 h. Lysates are digested using trypsin and LysC peptides are TMT labeled, mixed, and fractionated. Peptides are analyzed by mass spectrometry (MS) and protein abundances determined. (B) Volcano plot showing the log2 fold-change (x axis) and -log10 p-value (y axis) of all proteins identified by MS when comparing samples from USP7i-treated (FT671 or XL1774A) cells to samples from DMSO-treated cells. Each dot represents an individual protein. (C) Plot showing the log2 fold-change ratio of all proteins identified by MS when comparing samples from FT671-treated to DMSO-treated cells (x axis) vs the log2 fold-change ratio of all proteins identified by MS when comparing samples from XL177A-treated to DMSO-treated cells (y axis).

    Journal: bioRxiv

    Article Title: USP7 inhibition perturbs proteostasis and tumorigenesis in triple negative breast cancer

    doi: 10.1101/2025.01.28.635372

    Figure Lengend Snippet: (A) Schematic describing the quantitative proteomics workflow for the USP7 inhibitor (USP7i) analysis. SUM149, SUM159, and MDA-MB-231 TNBC cell lines were grown and treated with DMSO, 1 μM FT671, or 1 μM XL177A for 8 h. Lysates are digested using trypsin and LysC peptides are TMT labeled, mixed, and fractionated. Peptides are analyzed by mass spectrometry (MS) and protein abundances determined. (B) Volcano plot showing the log2 fold-change (x axis) and -log10 p-value (y axis) of all proteins identified by MS when comparing samples from USP7i-treated (FT671 or XL1774A) cells to samples from DMSO-treated cells. Each dot represents an individual protein. (C) Plot showing the log2 fold-change ratio of all proteins identified by MS when comparing samples from FT671-treated to DMSO-treated cells (x axis) vs the log2 fold-change ratio of all proteins identified by MS when comparing samples from XL177A-treated to DMSO-treated cells (y axis).

    Article Snippet: Tissue microarray (TMA) slides containing 110 TNBC cases were obtained from US Biomax (BRE1201; TissueArray.com ).

    Techniques: Labeling, Mass Spectrometry

    Schematic workflow for the identification and verification of biomarkers for sinonasal inverted papilloma (SNIP).

    Journal: International Journal of Medical Sciences

    Article Title: Identification and validation of Novel Estrogen Biosynthesis Biomarkers in Sinonasal Inverted Papilloma

    doi: 10.7150/ijms.101753

    Figure Lengend Snippet: Schematic workflow for the identification and verification of biomarkers for sinonasal inverted papilloma (SNIP).

    Article Snippet: Tissue microarray (TMA) slides containing SNIP, sinonasal malignancy, and control tissue samples were procured from SuperBioChips Laboratories (NH1001a; Seoul, Republic of Korea).

    Techniques:

    AKR1B10, CYP2C19, and CYP3A5 protein levels were specific to SNIP. Representative immunocytochemistry images of (A) SNIP tissue, sinonasal squamous cell carcinoma (SNSCC) tissue, and control tissue. (B) Relative fluorescence intensity of biomarkers in SNIP, SNSCC, and control tissues. Mann-Whitney U test was used to determine the significance. *p < 0.05; **p < 0.01. n.s, not significant.

    Journal: International Journal of Medical Sciences

    Article Title: Identification and validation of Novel Estrogen Biosynthesis Biomarkers in Sinonasal Inverted Papilloma

    doi: 10.7150/ijms.101753

    Figure Lengend Snippet: AKR1B10, CYP2C19, and CYP3A5 protein levels were specific to SNIP. Representative immunocytochemistry images of (A) SNIP tissue, sinonasal squamous cell carcinoma (SNSCC) tissue, and control tissue. (B) Relative fluorescence intensity of biomarkers in SNIP, SNSCC, and control tissues. Mann-Whitney U test was used to determine the significance. *p < 0.05; **p < 0.01. n.s, not significant.

    Article Snippet: Tissue microarray (TMA) slides containing SNIP, sinonasal malignancy, and control tissue samples were procured from SuperBioChips Laboratories (NH1001a; Seoul, Republic of Korea).

    Techniques: Immunocytochemistry, Control, Fluorescence, MANN-WHITNEY

    Upregulation of MHC class II antigen in human melanoma xenografts treated systemically with anle138b, and expression of α-synuclein, MHC class II, and MHC class I proteins in melanoma TMA cores. (a) A tissue section from a nontreated WM983-B tumor xenograft probed with an antibody to human MHC class II (HLA-DPB1) protein (pseudocolored green). (b) A tissue section from an anle138b-treated WM983-B tumor xenograft probed with an antibody to human MHC class II (HLA-DPB1) protein (pseudocolored green). (c) Fluorescence intensity level of expression of proteins – α-synuclein (pseudocolored red), MHC II (pseudocolored yellow), MHC I (pseudocolored green) – in areas, encircled by a white line, in tissue sections from three of the Stage II and from one of the Stage IV melanoma TMA cores in which α-synuclein or vice versa, MHC II, or MHC I protein was expressed more strongly. TMA, tissue microarray.

    Journal: Melanoma Research

    Article Title: Interfering with aggregated α-synuclein in advanced melanoma leads to a major upregulation of MHC class II proteins

    doi: 10.1097/CMR.0000000000000982

    Figure Lengend Snippet: Upregulation of MHC class II antigen in human melanoma xenografts treated systemically with anle138b, and expression of α-synuclein, MHC class II, and MHC class I proteins in melanoma TMA cores. (a) A tissue section from a nontreated WM983-B tumor xenograft probed with an antibody to human MHC class II (HLA-DPB1) protein (pseudocolored green). (b) A tissue section from an anle138b-treated WM983-B tumor xenograft probed with an antibody to human MHC class II (HLA-DPB1) protein (pseudocolored green). (c) Fluorescence intensity level of expression of proteins – α-synuclein (pseudocolored red), MHC II (pseudocolored yellow), MHC I (pseudocolored green) – in areas, encircled by a white line, in tissue sections from three of the Stage II and from one of the Stage IV melanoma TMA cores in which α-synuclein or vice versa, MHC II, or MHC I protein was expressed more strongly. TMA, tissue microarray.

    Article Snippet: Four melanoma tissue microarray (TMA) slides ( https://www.biomax.us/tissue-arrays/Melanoma/ME811 ), each containing two tissue sections from the same 39 cases of melanoma, and tissue sections from three cases of normal skin tissue were heated at 60 °C, deparaffinized and rehydrated.

    Techniques: Expressing, Fluorescence, Microarray